Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 993-999

  Medd, P ^a   Littlewood, S ^a   Danby, R ^b   Malladi, R ^a   Clifford, R ^a   Wareham, D ^a   Jeffery, K ^c   Ferry, B ^a   Roberts, D ^c   Peniket, A ^a   Littlewood, T ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

alemtuzumab; allogeneic transplantation; CMV; monoclonal gammopathy; paraprotein

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANCER THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; GROUPS BY AGE; HAZARD RATIO; HERPES SIMPLEX VIRUS; HODGKIN DISEASE; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PARAPROTEINEMIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RELAPSE; SERODIAGNOSIS; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CYTOMEGALOVIRUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VIRUS ACTIVATION;

EID: 79960192270     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.244     Document Type: Article

References (30)

1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
2. Pruzanski W, Cowan DH, Merrett RA, Freedman MH. IgG-1(kappa) M component after bone marrow transplantation. Clin Immunol Immunopathol 1973; 1: 311-318.
3. Rádl J, Dooren LJ, Eijsvoogel VP, van Went JJ, Hijmans W An immunological study during post-transplantation followup of a case of severe combined immunodeficiency. Clin Exp Immunol 1972; 10 367-382.
4. Fischer AM, Simon F, Deist FL, Blanche S, Griscelli C, Fischer A. Prospective study of the occurrence of monoclonal gammapathies following bone marrow transplantation in young children. Transplantation 1990; 49: 731-735. (Pubitemid 20146954)
5. Gerritsen EJ, van Tol MJ, Lankester AC, van der Weijden-Ragas CP, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation. Blood 1993; 82: 3493-3502. (Pubitemid 23356725)
6. Hammarström L, Smith CI. Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation 1987; 43: 447-449. (Pubitemid 17044764)
7. Hebart H, Einsele H, Klein R, Fischer I, Bühler S, Dietz K, et al. CMV infection after allogeneic bone marrow transplantation is associated with the occurrence of various autoantibodies and monoclonal gammopathies. Br J Haematol 1996; 95: 138-144.
8. Lim ZY, Ingram W, Brand R, Akthari M, Milojkovic D, Ho AY, et al. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplant 2007; 40: 747-752. (Pubitemid 47521534)
9. Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein HJ, Alper CA, et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989; 74: 2764-2768. (Pubitemid 20007804)
10. Nagashima T, Muroi K, Kawano-Yamamoto C, Komatsu N, Ozawa K. Paraproteinemia after hematopoietic stem cell transplantation. Leuk Lymphoma 2004; 45: 135-137. (Pubitemid 38181405)
11. Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 2000; 25: 723-728. (Pubitemid 30189512)
12. Maisnar V, Tichý M, Smolej L, Zák P, Radocha J, Palicka V, et al. Isotype class switching after transplantation in multiple myeloma. Neoplasma 2007; 54: 225-228.
13. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998; 91: 3518-3523. (Pubitemid 28193907)
14. Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375-382. (Pubitemid 26303927)
15. Chakalarovski C, Lang P, Buisson C, Bourgeon B, Intrator L, Deforge L, et al. Monoclonal immunoglobulins in patients with renal transplants: characterization, evolution and risk factors. Transpl Int 1992; 5(Suppl 1): S23-S25.
16. Drouet E, Chapuis-Cellier C, Bosshard S, Verniol C, Niveleau A, Touraine JL, et al. Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation. Clin Exp Immunol 1999; 118: 465-472.
17. Monk J, Calvin J, Price CP, Wreghitt TG. Oligoclonal banding in serum from heart-transplant recipients. Clin Chem 1989; 35: 431-434. (Pubitemid 19086694)
18. Myara I, Quenum G, Storogenko M, Tenenhaus D, Guillemain R, Moatti N. Monoclonal and oligoclonal gammopathies in heart-transplant recipients. Clin Chem 1991; 37: 1334-1337. (Pubitemid 21925967)
19. Lemoine A, Pham P, Azoulay D, Saliba F, Emile JF, Saffroy R, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 2001; 98: 1332-1338.
20. Pageaux GP, Bonnardet A, Picot MC, Perrigault PF, Coste V, Navarro F, et al. Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation 1998; 65: 397-400. (Pubitemid 28095970)
21. Touchard G, Pasdeloup T, Parpeix J, Hauet T, Bauwens M, Dumont G, et al. High prevalence and usual persistence of serum monoclonal immunoglobulins evidenced by sensitive methods in renal transplant recipients. Nephrol Dial Transplant 1997; 12: 1199-1203. (Pubitemid 27230557)
22. Bühler S, Laitinen K, Holthöfer H, Järvinen A, Schauman KO, Hedman K High rate of monoclonal gammopathy among immunocompetent subjects with primary cytomegalovirus infection. Clin Infect Dis 2002; 35 :1430-1433.
23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
24. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867-871. (Pubitemid 23321520)
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006; 33: S36-S43.
27. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, OGorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363. (Pubitemid 34627201)
28. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
29. DSa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, WattsMet al. T-and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-celldepleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123: 309-322. (Pubitemid 37305067)
30. Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone AH, et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 2003; 9: 198-205.